CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Net Inc. Y/Y Annual
Altimmune Inc   (ALT)
Other Ticker:  
 
 

ALT's Net Income Growth by Quarter and Year

Altimmune Inc 's Net Income results by quarter and year




ALT Net Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December -31.64 -21.66 -23.89 -10.62
III Quarter September -20.67 -23.52 -33.51 -17.77
II Quarter June -16.06 -20.11 -24.83 -16.77
I Quarter March -20.07 -19.43 -14.86 -3.89
FY   -88.44 -84.72 -97.09 -49.05



ALT Net Income fourth quarter 2023 Y/Y Growth Comment
Altimmune Inc in the fourth quarter 2023 recorded net loss of $ -31.64 millions.

According to the results reported in the fourth quarter 2023, Altimmune Inc achieved the best Net Income growth in Major Pharmaceutical Preparations industry. While Altimmune Inc ' s Net Income no change of % ranks overall at the positon no. in the fourth quarter 2023.


ALT Net Income ( Y/Y Growth %) 2023
 2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Altimmune Inc 's fourth quarter 2023 Net Income $ -31.64 millions ALT's Income Statement
Altimmune Inc 's fourth quarter 2022 Net Income $ -21.66 millions Quarterly ALT's Income Statement
New: More ALT's historic Net Income Growth >>


ALT Net Income (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -


Compare ALT Profitability >> Back to ALT Growth rate Comparisons >>


Net Income fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Income fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Altimmune Inc 's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ALT's IV. Quarter Q/Q Net Income Comment
Current net loss of -31.64 millions by Altimmune Inc come out even more unfavourable considering the net loss -20.67 millions in the third quarter.

Within Major Pharmaceutical Preparations industry Altimmune Inc achieved highest sequential Net Income growth. While Altimmune Inc 's Net Income growth quarter on quarter, overall rank is .


Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ALT's IV. Quarter Q/Q Net Income Comment
Current accomplishment of -31.64 millions by Altimmune Inc come out even more unfavourable compare to the net loss -20.67 millions in the previous quarter.

Within Major Pharmaceutical Preparations industry Altimmune Inc achieved highest sequential Net Income growth. While Altimmune Inc 's Net Income growth quarter on quarter, overall rank is .


Altimmune Inc 's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)
Cumulative Net Income 12 Months Ending $ -88.45 $ -78.47 $ -81.31 $ -85.36 $ -84.71
Y / Y Net Income Growth (TTM) - - - - -
Year on Year Net Income Growth Overall Ranking # # # # #
Seqeuential Net Income Change (TTM) - - - - -
Seq. Net Income Growth (TTM) Overall Ranking # # # # #

New: More ALT's historic Net Income Growth >>



Cumulative Net Income growth Comment
Altimmune Inc ' has realized cumulative trailing twelve months net loss of $ -88 millions in the Dec 31 2023 period.
The business is getting worse as the cumulative net loss is getting bigger from $ -78.47 millions in the twelve months ending a quarter before and $ -86.942321 millions for the twelve months ending in the quarter Dec 31 2022 Lucas Svensson wrote.

Altimmune Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Income growth Comment
Altimmune Inc ' has realized cumulative trailing twelve months net loss of $ -88 millions in the Dec 31 2023 period.
The situation is worsening as the cumulative net loss is getting bigger from $ -78.47 millions in the twelve months ending a quarter before and $ -86.942321 millions for the twelve months ending in the quarter a year ago.

Altimmune Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Income Growth
Major Pharmaceutical Preparations Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
ALT's Net Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for ALT's Competitors
Net Income Growth for Altimmune Inc 's Suppliers
Net Income Growth for ALT's Customers

You may also want to know
ALT's Annual Growth Rates ALT's Profitability Ratios ALT's Asset Turnover Ratio ALT's Dividend Growth
ALT's Roe ALT's Valuation Ratios ALT's Financial Strength Ratios ALT's Dividend Payout Ratio
ALT's Roa ALT's Inventory Turnover Ratio ALT's Growth Rates ALT's Dividend Comparisons



Companies with similar Net Income no change for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Net Income for the quarter ending Dec 31 2023
Tactile Systems Technology Inc 77.49%$ 77.494 millions
Quest Diagnostics Inc76.72%$ 76.724 millions
Dr Reddy s Laboratories Limited76.21%$ 76.206 millions
3m Company74.40%$ 74.401 millions
Electromed Inc 71.34%$ 71.341 millions
Tenet Healthcare Corp66.42%$ 66.423 millions
Alpha Pro Tech Ltd 66.36%$ 66.364 millions
Neurocrine Biosciences Inc 65.96%$ 65.955 millions
Cytek Biosciences Inc 64.76%$ 64.760 millions
United Therapeutics Corporation64.35%$ 64.345 millions
Fonar Corporation64.30%$ 64.296 millions
Select Medical Holdings Corp63.87%$ 63.868 millions
Abbott Laboratories54.31%$ 54.308 millions
Lemaitre Vascular Inc 50.44%$ 50.435 millions
Msa Safety Incorporated48.40%$ 48.401 millions
Halozyme Therapeutics Inc 47.98%$ 47.981 millions
Integer Holdings Corporation45.48%$ 45.482 millions
Cadre Holdings Inc 45.39%$ 45.386 millions
Chemed Corporation44.95%$ 44.952 millions
Viemed Healthcare Inc 42.62%$ 42.617 millions
Healthcare Services Group Inc 39.85%$ 39.848 millions
Ufp Technologies Inc 37.18%$ 37.178 millions
Catalyst Pharmaceuticals Inc 36.80%$ 36.799 millions
National Research Corporation33.38%$ 33.384 millions
West Pharmaceutical Services Inc 33.01%$ 33.010 millions
Baxter International Inc 32.97%$ 32.973 millions
Hologic Inc31.54%$ 31.537 millions
Semler Scientific Inc 31.25%$ 31.250 millions
Takeda Pharmaceutical Company Limited30.34%$ 30.344 millions
Orasure Technologies Inc28.99%$ 28.987 millions


Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com